Silence Therapeutics advanced its rare blood cancer siRNA program after announcing positive Phase II results for divesiran in polycythemia vera (PV). In the SANRECO trial (NCT05499013), Silence said the study met its primary endpoint, with an 88% response rate versus 19% in placebo-controlled groups, translating to more consistent hematocrit control and reduced reliance on frequent phlebotomies.